RxDoctor Payments Data

David Hernandez, MD

Pulmonary Disease · New Braunfels, TXNPI 1578505665

Payments from drug & device makers

$160in general payments, 2019–2025

Across 11 payments — averaging $14.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$49
  • Sanofi$23
  • Insmed, Inc.$17
  • United Therapeutics Corporation$16
  • CSL Behring$15
  • Inspire Medical Systems, Inc.$15
  • plus $24 from 2 others

What the payments were for

  • Food & beverage$12880%
  • Education$3120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$160 in reported general payments places this provider in the 15th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$250,152
Medicare patients
842
Services billed
2,848

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter143$114,267
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr190$106,875
Spiriva RespimatTiotropium Bromide147$101,248
Pirfenidone73$66,681
Breo ElliptaFluticasone/Vilanterol90$49,556
Stiolto RespimatTiotropium Br/Olodaterol Hcl84$45,032
Incruse ElliptaUmeclidinium Bromide40$16,972
Advair HfaFluticasone Propion/Salmeterol28$13,670
Albuterol Sulfate HfaAlbuterol Sulfate365$13,083
Arnuity ElliptaFluticasone Furoate23$9,732
SymbicortBudesonide/Formoterol Fumarate21$6,005
Fluticasone-SalmeterolFluticasone Propion/Salmeterol34$5,340
Ventolin HfaAlbuterol Sulfate53$4,682
BreynaBudesonide/Formoterol Fumarate13$3,266
Levalbuterol Tartrate HfaLevalbuterol Tartrate53$3,061

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$49$297,402486 claims
AstraZenecaSymbicort$12$6,00521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 904 pulmonary disease providers in Texas.

Other pulmonary disease in New Braunfels

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →